Synopsis
Synopsis
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
2. Amn 107
3. Amn-107
4. Amn107
5. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
6. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate
7. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:1:2)
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:2)
9. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (2:2:3)
10. Nilotinib
11. Nilotinib Dihydrochloride Dihydrate
12. Nilotinib Hydrochloride Anhydrous
13. Nilotinib Hydrochloride Dihydrate
14. Nilotinib Hydrochloride Hydrate
15. Nilotinib Hydrochloride Monohydrate
16. Nilotinib Hydrochloride Sesquihydrate
17. Tasigna
1. 923288-95-3
2. Nilotinib Hydrochloride Anhydrous
3. Nilotinib Hcl
4. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide Hydrochloride
5. Nilotinib (hydrochloride)
6. K37n7byx3x
7. 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrochloride
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
9. Nilotinib (as Hydrochloride)
10. Unii-k37n7byx3x
11. Amn 107 Hydrochloride
12. Amn-107 Hcl
13. Schembl434496
14. Dtxsid60238968
15. Bcp29532
16. Hy-10159b
17. S5205
18. Ccg-270077
19. Nilotinib Hydrochloride [vandf]
20. Bn164657
21. Nilotinib Hydrochloride Monohydrate- Bio-x
22. Cs-0085192
23. Nilotinib Hydrochloride [orange Book]
24. Nilotinib Hydrochloride Anhydrous [who-dd]
25. Q27281888
26. Nilotinib Hcl;amn 107; Amn107; Amn-107; Nilotinib Hydrochloride Anhydrous
27. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamidehydrochloride
28. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide Hydrochloride
29. 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Hydrochloride
Molecular Weight | 566.0 g/mol |
---|---|
Molecular Formula | C28H23ClF3N7O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 6 |
Exact Mass | 565.1604706 g/mol |
Monoisotopic Mass | 565.1604706 g/mol |
Topological Polar Surface Area | 97.6 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 817 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2022-09-15
Pay. Date : 2022-08-22
DMF Number : 37161
Submission : 2022-07-08
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2016-03-16
Pay. Date : 2016-02-04
DMF Number : 30088
Submission : 2015-12-31
Status : Active
Type : II
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39648
Submission : 2024-03-27
Status : Active
Type : II
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37531
Submission : 2022-09-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-07-05
Pay. Date : 2016-05-05
DMF Number : 30098
Submission : 2015-12-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30164
Submission : 2015-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26497
Submission : 2012-09-28
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-06-04
Pay. Date : 2017-05-17
DMF Number : 31693
Submission : 2017-04-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-13
Pay. Date : 2014-03-19
DMF Number : 28102
Submission : 2014-07-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25338
Submission : 2011-09-28
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-01-18
US Patent Number : 8415363*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22068
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-01-18
Patent Expiration Date : 2024-01-04
US Patent Number : 7169791*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22068
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2024-01-04
Patent Expiration Date : 2026-07-18
US Patent Number : 8415363
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 22068
Patent Use Code : U-1407
Delist Requested :
Patent Use Description : TREATMENT OF NEWLY DIA...
Patent Expiration Date : 2026-07-18
Patent Expiration Date : 2024-01-04
US Patent Number : 7169791*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22068
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2024-01-04
Patent Expiration Date : 2027-01-18
US Patent Number : 8415363*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22068
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-01-18
Patent Expiration Date : 2029-02-23
US Patent Number : 8163904*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22068
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-02-23
Patent Expiration Date : 2032-04-07
US Patent Number : 9061029
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 22068
Patent Use Code : U-1374
Delist Requested :
Patent Use Description : TREATMENT OF PHILADELP...
Patent Expiration Date : 2032-04-07
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?